Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 19,403Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Dr Reddy’s Laboratories Limited

02 1Ash Stevens LLC

03 1Biocon Limited

04 1ESCIENTIA ADVANCED SCIENCES PRIVATE LIMITED

05 3MSN Laboratories Private Limited

06 1Piramal Healthcare (Canada) Limited

07 1STERLING SPA

08 1Shanghai Huilun Jiangsu Pharmaceutical Co., Ltd.

09 3Sterling Chemical Malta Ltd

10 1Valary Lab Private Limited

filter clear-filterReset all filters

filter clear-filterReset all filters

PharmaCompass

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

CABOZANTINIB

NDC Package Code : 71796-059

Start Marketing Date : 2023-03-31

End Marketing Date : 2026-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Dr Reddy Company Banner

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 48957-0121

Start Marketing Date : 2021-02-26

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

AACR Annual meeting
Not Confirmed
arrow

04

AACR Annual meeting
Not Confirmed
arrow

05

AACR Annual meeting
Not Confirmed
arrow

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 55679-116

Start Marketing Date : 2012-11-15

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 59057-013

Start Marketing Date : 2022-08-31

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

CABOZANTINIB

NDC Package Code : 59057-018

Start Marketing Date : 2024-09-02

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

CABOZANTINIB

NDC Package Code : 59057-019

Start Marketing Date : 2024-09-02

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

AACR Annual meeting
Not Confirmed
arrow

Looking for 1140909-48-3 / Cabozantinib S-Malate API manufacturers, exporters & distributors?

Cabozantinib S-Malate manufacturers, exporters & distributors 1

53

PharmaCompass offers a list of Cabozantinib S-Malate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cabozantinib S-Malate manufacturer or Cabozantinib S-Malate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cabozantinib S-Malate manufacturer or Cabozantinib S-Malate supplier.

PharmaCompass also assists you with knowing the Cabozantinib S-Malate API Price utilized in the formulation of products. Cabozantinib S-Malate API Price is not always fixed or binding as the Cabozantinib S-Malate Price is obtained through a variety of data sources. The Cabozantinib S-Malate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Cabozantinib S-Malate

Synonyms

1140909-48-3, Cabozantinib malate, Cabozantinib (s)-malate, Cabometyx, Cabozantinib malate (xl184), Xl184

Cas Number

1140909-48-3

Unique Ingredient Identifier (UNII)

DR7ST46X58

About Cabozantinib S-Malate

Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.

CABOMETYX Manufacturers

A CABOMETYX manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of CABOMETYX, including repackagers and relabelers. The FDA regulates CABOMETYX manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. CABOMETYX API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of CABOMETYX manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

CABOMETYX Suppliers

A CABOMETYX supplier is an individual or a company that provides CABOMETYX active pharmaceutical ingredient (API) or CABOMETYX finished formulations upon request. The CABOMETYX suppliers may include CABOMETYX API manufacturers, exporters, distributors and traders.

click here to find a list of CABOMETYX suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

CABOMETYX NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing CABOMETYX as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for CABOMETYX API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture CABOMETYX as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain CABOMETYX and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a CABOMETYX NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of CABOMETYX suppliers with NDC on PharmaCompass.

CABOMETYX Manufacturers | Traders | Suppliers

CABOMETYX Manufacturers, Traders, Suppliers 1
Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.